Full Press Release Details
Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.
Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.)
Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 London time / 09:00 New York time.
(For Europe: Due to the U.S. time switch, our conference call will be held one hour earlier than usual.)
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service available 15 minutes before call start
U.S.: +1 646 828 8193
UK: +44 (0)330 165 3656
GER: +49 (0)69 6610 2491
Conference ID: 4759185
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast - Click here: Access Webcast
A conference call replay will be available by using the following link:
Contact: IR@qiagen.com
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to
Insight solutions that enable customers to gain valuable molecular insights from samples containing
the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from
blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable
insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN
provides solutions to more than 500,000 customers around the world in Molecular Diagnostics
(human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2023, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.